JCB logo
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online July 14, 2008
doi:10.1083/jcb.200806069
The Journal of Cell Biology, Vol. 182, No. 1, 7-9
The Rockefeller University Press, 0021-9525 $30.00
© 2008 Di Fiore
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Di Fiore, P. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Fiore, P. P.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Comment

 Playing both sides: nucleophosmin between tumor suppression and oncogenesis

Pier Paolo Di Fiore

Istituto FIRC di Oncologia Molecolare (IFOM), 20139 Milan, Italy
Dipartimento di Medicina, Chirurgia ed Odontoiatria, Universitá degli Studi di Milano, 20122 Milan, Italy
Istituto Europeo di Oncologia, 20141 Milan, Italy

Correspondence to P.P. Di Fiore: pierpaolo.difiore{at}ifom-ieo-campus.it

Nucleophosmin (NPM) is frequently mutated in acute myeloid leukemias and is thought to act as both a proto-oncogene and a tumor suppressor. Although genetic and molecular evidence has shed light on the mechanisms of NPM-mediated tumor suppression, the potential role of NPM mutants as oncogenes remains ill defined. Now, new data provide a straightforward mechanism for this latter function, as NPM is shown to regulate the stability and the function of MYC. Remarkably, the same leitmotif of "placing a critical cell regulator in the wrong place at the wrong time" appears to underscore all the cancer-promoting activities of mutated NPM.

Abbreviations used in this paper: AML, acute myeloid leukemia; NPM, nucleophosmin.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7{gamma}
Paola Bonetti, Teresa Davoli, Cristina Sironi, Bruno Amati, Pier Giuseppe Pelicci, and Emanuela Colombo
J. Cell Biol. 2008 182: 19-26. [Abstract] [Full Text] [PDF]





  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents